30 – 55% af patienterne i de kliniske studier hos patienter med NHL og hos 30 – 50% af patienterne i de kliniske studier med CLL.
Infectious events (predominantly bacterial and viral) occurred in approximately 30-55% of patients during clinical trials in patients with NHL and in 30-50% of patients during clinical trial in patients with CLL.